Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?

Lignende værker

• Symptoms of endocrine treatment and outcome in the BIG 1–98 study
  af: Huober, J., et al.
  Udgivet: (2013)
• Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
  af: Koeberle, Dieter, et al.
  Udgivet: (2007)
• Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
  af: Koeberle, Dieter, et al.
  Udgivet: (2007)
• Understanding the role of obesity in endocrine therapy for postmenopausal breast cancer: significance of the BIG 1–98 and ATAC trial data
  af: Sixten Harborg, et al.
  Udgivet: (2025-07-01)
• Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
  af: Munzone, E., et al.
  Udgivet: (2015)